Mode
Text Size
Log in / Sign up
N/A N=572

Assessing the WAVE Extra Soft Coil in Intracranial Aneurysms and Comparing Imaging Modalities

Aneurysm, Brain

Enrolled (actual)
572
Serious AEs
24.5%
Results posted
Mar 2025
Primary outcome: Primary: Efficacy: Adequate Occlusion — 366 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
WAVE, as part of the SMART COIL System (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Penumbra Inc.
Primary completion
Aug 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Efficacy: Adequate Occlusion
366
PRIMARY
Safety: Serious Adverse Events (SAEs)
53
PRIMARY
Safety: Device-Related SAE
6
SECONDARY
Efficacy: Occlusion Rate
361; 137; 72
SECONDARY
Efficacy: Retreatment Rate
45
SECONDARY
Efficacy: Aneurysm Occlusion Raymond I
313
SECONDARY
Efficacy: Aneurysm Occlusion Raymond I
313
SECONDARY
Efficacy: Aneurysm Recanalization or Progressive Thrombosis
110; 235; 50
SECONDARY
Safety: Major Ipsilateral Stroke
10
SECONDARY
Safety: Device-Related SAE
6
SECONDARY
Safety: Morbidity and Mortality
123

Summary

The objective of this study is to demonstrate the safety and efficacy of the Penumbra SMART COIL® System, including the WAVE™ Extra Soft Coils (WAVE) as a fill and finish coil, in the treatment of intracranial aneurysms. Imaging will be analyzed by an independent core lab to assess aneurysm occlusion rates and perform a comparative analysis between imaging modalities.

Eligibility Criteria

Inclusion Criteria

  • Patient age ≥ 18 years
  • Patient having embolization of intracranial aneurysms
  • WAVE Extra Soft Coil is final finishing coil
  • Penumbra SMART COIL System accounts for at least 75% of total number of coils implanted
  • Informed consent obtained per Institutional Review Board/Ethics Committee (IRB/EC) requirements

Exclusion Criteria

  • Life expectancy less than 1 year
  • Patient previously enrolled in the SURF Study
  • Known multiple intracranial aneurysms requiring treatment during index procedure
  • Patient is unwilling or unable to comply with protocol follow up schedule and/or based on the Investigator's judgment the patient is not a good study candidate
  • Participation in an interventional drug or device study that may confound the results of the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04106583). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search